Isn't Biogen supposed to be a leading science company in neurology? Maybe a biotech run by a salesman with a company linkedin profile full of (fictitious) social virtue posts has lost its focus. Five years after Scangos, any new drugs from internal R&D or forward progress from a CEO who has taken home 50M+ while internal talent fled? Can the analysts be honest here or do the club insider rules prohibit it?
Congratulations on a great quarter with revenue down 25 percent. Thank you for calling on me for a question and I look forward to attending your next party. Can you update us on daclizumab?